share_log

EyePoint Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

EyePoint Pharmaceuticals | 144:擬議出售證券

美股SEC公告 ·  01/23 00:00

Moomoo AI 已提取核心訊息

EyePoint Pharmaceuticals, Inc. Director Nancy Lurker is set to sell 5,044 shares of common stock on 01/23/2024, as per the latest SEC filings. The shares to be sold have an aggregate market value of approximately $125,949.69. The securities were acquired through open market purchases and stock options between October 2019 and February 2020. This planned sale follows a previous transaction where Lurker sold 20,000 shares for a total gross proceed of $415,164 on 12/04/2023.
EyePoint Pharmaceuticals, Inc. Director Nancy Lurker is set to sell 5,044 shares of common stock on 01/23/2024, as per the latest SEC filings. The shares to be sold have an aggregate market value of approximately $125,949.69. The securities were acquired through open market purchases and stock options between October 2019 and February 2020. This planned sale follows a previous transaction where Lurker sold 20,000 shares for a total gross proceed of $415,164 on 12/04/2023.
根據美國證券交易委員會的最新文件,EyePoint Pharmicals, Inc.董事南希·盧克定於2024年1月23日出售5,044股普通股。待售股票的總市值約爲125,949.69美元。這些證券是在2019年10月至2020年2月期間通過公開市場購買和股票期權收購的。此次計劃出售是在之前的一筆交易之後進行的,在該交易中,Lurker於2023年4月12日出售了20,000股股票,總收益爲415,164美元。
根據美國證券交易委員會的最新文件,EyePoint Pharmicals, Inc.董事南希·盧克定於2024年1月23日出售5,044股普通股。待售股票的總市值約爲125,949.69美元。這些證券是在2019年10月至2020年2月期間通過公開市場購買和股票期權收購的。此次計劃出售是在之前的一筆交易之後進行的,在該交易中,Lurker於2023年4月12日出售了20,000股股票,總收益爲415,164美元。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息